Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;27(11):1613-1617.
doi: 10.18553/jmcp.2021.27.11.1613.

The effectiveness and value of aducanumab for Alzheimer's disease

Patricia G Synnott  1 , Melanie D Whittington  2 , Grace A Lin  3 , David M Rind  2 , Steven D Pearson  2
Affiliations

The effectiveness and value of aducanumab for Alzheimer's disease

Patricia G Synnott et al. J Manag Care Spec Pharm. 2021 Nov.

Abstract

DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from AbbVie, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Sun Life Financial, uniQure, and United Healthcare. Whittington, Rind, and Pearson are employed by ICER. Through their affiliated institutions, Synnott and Lin received funding from ICER for the work described in this summary. In addition, Synnott reports support from Biogen for the Tufts Medical Center Cost-Effectiveness Analysis Registry, which is maintained by the Center for the Evaluation of Value and Risk in Health.

PubMed Disclaimer

Conflict of interest statement

Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions.

ICER’s annual policy summit is supported by dues from AbbVie, America’s Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Sun Life Financial, uniQure, and United Healthcare.

Whittington, Rind, and Pearson are employed by ICER. Through their affiliated institutions, Synnott and Lin received funding from ICER for the work described in this summary. In addition, Synnott reports support from Biogen for the Tufts Medical Center Cost-Effectiveness Analysis Registry, which is maintained by the Center for the Evaluation of Value and Risk in Health.

References

    1. US Food and Drug Administration. FDA grants accelerated approval for Alzheimer’s drug [press release]. June 7, 2021. Accessed October 4, 2021. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerat...
    1. Lin GA, Whittington M, Synnott PG, et al. . Aducanumab for Alzheimer’s Disease: effectiveness and value. Final evidence report and meeting summary. Institute for Clinical and Economic Review. August 5, 2021. Accessed October 4, 2021. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Final_Report_080521...
    1. US Food and Drug Administration. Combined FDA and Applicant PCNS Drugs Advisory Committee briefing document. November 6, 2020. Accessed October 4, 2021. https://www.fda.gov/media/143502/download
    1. Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement (N Y). 2019;5:354-63. - PMC - PubMed
    1. Ackley SF, Zimmerman SC, Brenowitz WD, et al. . Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372:n156. - PMC - PubMed

MeSH terms

Substances